The global cell line development market is estimated to reach USD 10,838.5 Million by 2028, at a CAGR of 12.01% during the forecast period from 2021 to 2028. Rising demand for monoclonal antibodies is one of the major driving factors which promotes the growth of the market. Rising demand from vaccine production is also considered an important driving factor that promotes the growth of the market. The growing demand from the end-users followed by technological advancement is one of the major factors that assists in driving the growth of the market. High cost of the process is one of the major restraint factors which directly affects the growth of the market. Nonetheless, ongoing research and development in the field of medical sciences and biotechnology will bring huge growth opportunities during the forecasted year.
Stable cell lines are extensively used in different important applications which include, drug screening, biologics (e.g. recombinant protein and monoclonal antibody) production, and gene functional studies. The process of developing stable cell lines often starts with transfecting selected host cells, typically CHO or HEK 293 cells, with desired plasmids. After transfection, researchers then screen and quantify high-expressing clones. Once these high producers are identified, the cell lines and/or the proteins produced by the cells are validated.
The manual screening methods traditionally used for cell line development are time-consuming and labor-intensive, creating a great demand for high throughput, automated solutions for such efforts. The general workflow below helps identify the systems that can aid in your research.
An unexpected problem hit the ground in a form of the COVID 19 pandemic. The virus first discovered in 2019 in China, and later it spread across the whole world. The demand for healthcare products rises rapidly. The whole world looking after the manufacturing of vaccines. Effective storage is the most common problem. According to current data, most of the vaccines should be stored in between 2 to 8 degrees Celsius. Looking at the current demand for vaccines and related products, the demand for cell line development will go increase. The COVID 19 pandemic shown a positive impact on the cell line development and the freezers market.
Based on type, the cell line development market is classified into six types equipment, media, and reagent. The equipment segment is further classified into Biosafety Cabinets, Cell Counters and Viability Systems, incubators, Centrifuges, Bioreactors, Storage Equipment, Automated Systems, Microscopes, Filtration Systems, and Others. The media and reagent segment is expected to grow with the highest CAGR% during the forecasted year from 2021 to 2028. The equipment segment was near 1731.11 million. Increasing demand from the end-user industry is one of the major factors which propel the growth of the market.
Based on the source, the global cell line development market is classified into mammalian and non-mammalian. The mammalian holds the largest market share in terms of revenue generation. The same segment is expected to grow during the forecasted year from 2021 to 2028. The mammalian segment contributes more than 80% of the total market share in the year 2020. Mammalian cell culture has a bright demand in the biopharmaceutical industry. The mammalian used in industry includes Dog/Kidney, Hamster/Ovary, Green Monkey/Kidney, Human/Lungs, Human/Spleen, and others. Some of the important cell lines are CHO cells, VERO cells, Sp2/0 Myeloma, etc.
Based on the type of cell lines, the global cell line development market is classified into primary cell lines, continuous cell lines, hybridomas, and recombinant cell lines. The continuous cell lines will grow at the highest CAGR% during the forecasted year. The hybridomas segment contribute more than 25% of the global market share in the year 2020. Rising demand for monoclonal antibodies is the most driving factor that promotes the growth of the hybridomas market.
Based on the application, the cell line development market is classified into bioproduction, tissue engineering & regenerative medicines, toxicity testing, research, and drug discovery. The tissue engineering & regenerative medicines segment generates more than 600 million in the year 2019.
Adroit Market Research report on global cell line development market gives a holistic view of the market from 2018 to 2028, which includes factors such as market drivers, restraints, opportunities and challenges. The market has been studied for historic years from 2018 to 2019, with the base year of estimation as 2020 and forecast from 2021 to 2026. The report covers the current status and future traits of the market at global as well as country level. In addition, the study also assesses the market based on Porter's five forces analysis and positions the key players based on their product portfolio, geographic footprint, strategic initiatives and overall revenue. Prominent players operating in the global cell line development market have been studied in detail.
The global cell line development market report is classified into five major regions North America, Europe, Asia Pacific, Latin America & Middle East, and Africa. In terms of revenue, North America holds the largest market share in the year 2020. The region accounted for more than 49% market share of the total cell line development market. Growing awareness and rising per capita healthcare expenditure is the major contributing factor that assists in driving the growth of the market. Advanced health care infrastructure followed by skilled medical staff also helps in propelling the growth of the market. Europe holds the second-largest market in terms of revenue generation. UK, Germany, and France are the major contributing countries for this region. The rising geriatric population across Europe is the major contributing factor that leads to the advancement of the medical sector. Asia Pacific market is expected to grow at the highest CAGR% in the coming years. The growth is mainly associated with economic growth in this region. The untapped market of India and China are considered as huge business market opportunities for the major market players.
The major players operating in the global cell line development market include but are not limited to American Type Culture Collection (ATCC), Lonza Group AG , Thermo Fisher Scientific, Inc., GE Healthcare, Sigma-Aldrich Corporation, Selexis SA , European Collection of Cell Cultures (ECACC), Corning, Inc., WuXi AppTec, Inc., Sartorious AG and among others. The proliferation of local manufacturers is also significant in this market, thus intensifying the prevalent competition.
Key Segments of the Global Cell line development market
Product Type Overview, 2018-2028 (USD Million)
- Equipment
- Biosafety Cabinets
- Cell Counters and Viability Systems
- Incubators
- Centrifuges
- Bioreactors
- Storage Equipment
- Cell Culture Refrigerators and Freezers
- Cell Culture Cryogenic Storage
- Automated Systems
- Microscopes
- Filtration Systems
- Others
- Media and Reagents
- Serum
- Fetal Bovine Serum
- Adult Bovine Serum
- Other Animal Serum
- Media
- Minimum Essential Media
- Reduced Serum Media
- Serum-free Media
- Reagents
- Supplements and Growth Factors
- Buffers and Chemicals
- Cell Dissociation Reagents
- Cryopreservative Reagents
- Others
- Serum
Type Overview, 2018-2028 (USD Million)
- Mammalians
- Insects
- Amphibians
Application Overview, 2018-2028 (USD Million)
- Bioproduction
- Diagnostics
- Vaccines
- Recombinant Protein Therapeutics
- Tissue Engineering & Regenerative Medicines
- Toxicity Testing
- Research
- Drug Discovery
Regional Overview, 2018-2028 (USD Million)
- North America
- U.S.
- Canada
- Europe
- Germany
- United Kingdom
- France
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa